HIV

Anmerkungen:

• Self-limiting, lasts 1-2 weeks and occurs in 30-60% HIV pts

1. Sore throat, fever, malaise, arthralgia, mouth ulcer, maculopapular rash

1. weight loss, fatigue, lymphadenopathy, night sweats, diarrhoea
2. Recurrent candidiasis
3. recurrent / extensive genital warts
4. shingles
5. oral hairy leucoplakia
6. Worsening eczema / psoriasis

Anmerkungen:

• Mean time to progession - 7-10 years, CD4+ less than 200

1. Respiratory
   1. TB

      Anmerkungen:

      • Early and late HIV present differently - early - normal presentation. advanced - malaise, fever, fatigue weight loss, CXR may be normal or pleural effusion, shadowing. tuberculin may bne negative and smear negative
      1. Presents atypically; PUO, minimal respiratory features, extra-pulmonary / disseminated disease
      2. CXR - cavitating lesions but atypical in HIV
      3. HIV / TB co infection - have a deleterious affect on each other
   2. pneumocystis pneumonia (PCP)

      Anmerkungen:

      • Pneumocystis jirovecii
      1. Gradual onset breathlessness, fever, dry cough
      2. exertional desaturation, bilateral crackles
   3. Cryptococcal

      Anmerkungen:

      • Lung, meningeal or wound infection. pigeon droppings (neoformans)
   4. Cryptosporidiosis

      Anmerkungen:

      • Infects intestine - diarrhoea - potentially fatal in AIDs
   5. Lymphocytic interstitial pneumonia

      Anmerkungen:

      • Dry cough, breathlessness
2. Malignancy
   1. Kaposis sarcoma

      Anmerkungen:

      • HHV 8 virus. commonly presents with lesions on tip of the nose - dermatological condition
   2. Cervical carcinoma
   3. Lymphoma
      1. Systemic NHL

         Anmerkungen:

         • 30% of malignancy death in HIV - associated with EBV
         1. Extranodal disease - meninges and bone marrow
3. CNS

   Anmerkungen:

   • usually at CD4 less than 100
   1. Encephalitis

      Anmerkungen:

      • Diffuse brain disorder
      1. CMV
      2. HSV
      3. HIV encephalopathy (AIDS-dementia complex)
   2. Focal / meningeal
      1. Tuberculous
      2. Cryptococcal
      3. CNS lymphoma

         Anmerkungen:

         • Single enhancing brain lesion - strongly associated with EBV. primary NHL
         • Associated with EBV - diagnosis by detection in CSF
         1. Focal neurological deficits
      4. Progressive multifocal leucoencephalopathy

         Anmerkungen:

         • focal areas of demylelination
   3. Toxoplasmosis

      Anmerkungen:

      • Multiple ring enhanced brain lesions
4. others
   1. Mucocutaneous herpes simplex
   2. Peripheral neuropathy
   3. HIV associated wasting
   4. CMV retinitis

      Anmerkungen:

      • CD4 less than 100
5. GI disorders
   1. Oral: herpes simplex, candida, apthous, hairy leucoplakia
   2. Diarrhoea; bacterial; salmonella, campylobacter, mycobacterium avium complex, protozoa; cryptosporidiosis, microsporidia, CMV
   3. Oesphageal; candidiasis, CMV oesophagitis, herpes simplex
6. Dermatological
   1. Psoriasis, achnes, seborrhoeic dermatitis
   2. itchy folliculitis
   3. Dermatophtosis
   4. crusted scabies
   5. VZV / HSV
   6. Molluscum contagiosum
   7. Recalcitrant warts

Anmerkungen:

• 5-10% HIV patients - little / no detectable virus in blood

1. cervical smears

   Anmerkungen:

   • Yearly smears as progression to malignancy to rapid
2. CD4 count

   Anmerkungen:

   • Indicates immune status. measure every 3 months
   1. less than 200 cells /mm - AIDs
3. Plasma viral load

   Anmerkungen:

   • measure every 3 months
4. Screen for other STIs

Anmerkungen:

• used in resource poor settings, window period - 3-6 months (need to wait for seroconversion?)

Anmerkungen:

• Window period 6 wks - 3 mnths (can be 15 days)

Anmerkungen:

• Generally started at CD4 counts less than 350 or opportunistic infection - balance risks and benefits

1. Risks
   1. drug toxicity
      1. Immediate - hypersensitivity reaction, acute hepatitis, pancreatitis, lactic acidosis
      2. Long term; increased MI risk, lipatrophy, lipodystrophy, nausea, diarrhoea
   2. Drug resistance

      Anmerkungen:

      • Need compliance of 95% to prevent resistance
2. Benefits
   1. Preservation of immune funtcion
   2. Decrease risk of transmission
   3. Prolonged disease free survival
   4. Reduced mortality from liver disease and malignancy
3. Types
   1. Nucleoside / tide reverse transcriptase inhibitors (NRTIs)
   2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
   3. Protease inhibitor
4. 2 NRTIs and 1 NNRTI / PI